Associated tags: CD3, Female, Therapy, Cancer, CLDN6, Context, Pharmaceutical industry, Breast, Immunotherapy, Endometrial cancer, Patient, Breast cancer, Research, Ovary, IND
Locations: PHILADELPHIA, PA, US
Context,
FDA,
CD3,
CLDN6,
Food,
Cancer,
Research,
Insurance,
Conference,
Growth,
IND,
Patient,
Clinical trial,
Investigational New Drug,
Pharmaceutical industry PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights.
Key Points:
- PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights.
- “We believe Context has had a great start to 2024 including achieving significant regulatory goals, demonstrating robust progress, and positioning us for future growth.
- Also in May 2024, Context announced that the FDA cleared its IND for CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, submitted in March 2024.
- Context reported a net loss of $3.7 million for the first quarter of 2024, as compared to $6.3 million for the same period in 2023.
Drug discovery,
Cancer,
Patient,
CLDN6,
Trial of the century,
IND,
Toxicology,
Context,
Physician,
Food,
Pharmaceutical industry The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
Key Points:
- The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 (CLDN6)-positive gynecologic and testicular cancers.
- “Our IND submission for CTIM-76 is a significant milestone for Context,” said Martin Lehr, CEO of Context.
- The IND application includes extensive manufacturing, preclinical, and toxicology data to support a first-in-human trial.
- I am incredibly proud of the entire Context team who worked tirelessly to complete this IND submission.
Research,
Conference,
Cancer,
Immunotherapy,
New Drug Application,
Integral,
CLDN6,
Insurance,
Society,
Trial of the century,
IND,
CD3,
SITC,
Context,
Annual general meeting,
Food PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights.
Key Points:
- “During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study.
- The preclinical data further support CTIM-76’s differentiated product profile, including its potential to address limitations of first-generation CLDN6-targeted clinical-stage therapies,” said Martin Lehr, CEO of Context.
- In November 2023, Context presented preclinical data at the SITC 38th Annual Meeting that demonstrated CTIM-76 was well tolerated and induced dose-proportional tumor regressions in xenograft models of CLDN6-positive cancer.
- Context reported a net loss of $24.0 million for 2023, as compared to $14.8 million for the same period in 2022.
Retrieved on:
Thursday, November 9, 2023
Annual general meeting,
Food,
IND,
Insurance,
CLDN6,
Research,
Immunotherapy,
New Drug Application,
Conference,
Trial of the century,
SITC,
Toxicity,
Context,
Society,
CD3,
Cryptocurrency,
Pharmaceutical industry,
Vaccine PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights.
Key Points:
- Cash and cash equivalents of $21.7 million as of September 30, 2023
PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the third quarter ended September 30, 2023, and reported on recent and upcoming business highlights.
- Research and development (“R&D”) expenses were $4.5 million for the third quarter 2023, as compared to $2.1 million for the same period in 2022.
- General and administrative expenses were $1.7 million for the third quarter 2023, as compared to $2.0 million for the same period in 2022.
- Context reported a net loss of $5.9 million for the third quarter 2023, as compared to $3.9 million for the same period in 2022.
Retrieved on:
Tuesday, October 31, 2023
IND,
CD3,
Lehr,
Context,
CLDN6,
SITC,
Immunotherapy,
Annual general meeting,
Benchmarking,
Path integral molecular dynamics,
Society,
Patient,
Drug discovery,
Toxicity,
Abstract,
Fine chemical,
Pharmaceutical industry PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
Key Points:
- PHILADELPHIA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced encouraging preclinical data regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody.
- Findings from Context’s research team, in conjunction with development partner Integral Molecular, illustrate the potential of CTIM-76 to treat CLDN6-positive tumors.
- Notably:
CTIM-76 was shown to have high potency and target selectivity in both binding and cytotoxicity assays.
- “The preclinical data at this year's SITC meeting will illustrate the potential of CTIM-76 to target CLDN6,” said Lehr.
Retrieved on:
Wednesday, September 27, 2023
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.
Key Points:
- PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023, at the San Diego Convention Center in San Diego, CA.
- Details of the presentation are as follows:
Location: Exhibit Halls A and B1, San Diego Convention Center
For more information and to view the abstract, visit the SITC 38th Annual Meeting website .
Retrieved on:
Wednesday, August 9, 2023
Insurance,
Cell death,
CD3,
Path integral molecular dynamics,
Research,
CLDN6,
Immunotherapy,
Lung,
Context,
IND,
Society,
Conference,
Cryptocurrency,
Pharmaceutical industry,
Vaccine,
Rare-earth element PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights.
Key Points:
- Cash and cash equivalents of $25.1 million as of June 30, 2023
PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2023, and reported on recent and upcoming business highlights.
- “During the second quarter of this year, Context continued development of our preclinical asset CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody.
- General and administrative expenses were $1.8 million for the second quarter 2023, as compared to $2.0 million for the same period in 2022.
- Context reported a net loss of $5.0 million for the second quarter 2023, as compared to $4.0 million for the same period in 2022.
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023.
Key Points:
- PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in August 2023.
- Details of the events are as follows:
BTIG Virtual Biotechnology Conference 2023: Context CEO Martin Lehr will participate in a fireside chat taking place on Monday, August 7, 2023, at 10:30 a.m.
- Context will also participate in one-on-one meetings.
- H.C. Wainwright Immune Cell Engager Virtual Conference: Context CEO Martin Lehr will participate in a fireside chat taking place Thursday, August 17, 2023, at 11:30 a.m.
Diamond,
AACR,
Cell death,
CD3,
Neoplasm,
Clinical trial,
Cancer,
Path integral molecular dynamics,
American Association for Cancer Research,
G&A,
Research,
CLDN6,
Immunotherapy,
Lung,
Investigational New Drug,
Patient,
Context,
R,
IND,
Conference,
Cryptocurrency,
Life insurance PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced its financial results for the first quarter ended March 31, 2023, and reported on recent and upcoming business highlights.
Key Points:
- In April 2023, participated in the Diamond Equity Emerging Growth Invitational Investor Conference and the 22nd Annual Needham Virtual Healthcare Conference.
- Research and development (R&D) expenses were $4.5 million for first quarter 2023, as compared to $1.4 million for the same period in 2022.
- General and administrative (G&A) expenses were $2.1 million for both the first quarter 2023 and the first quarter 2022.
- Context reported a net loss of $6.3 million for the first quarter 2023, as compared to $3.4 million for the same period in 2022.
PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023.
Key Points:
- PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023.
- Details of the events are as follows:
Diamond Equity Emerging Growth Invitational Investor Conference: The Company will present on Wednesday, April 5 at 9:40 a.m.
- ET.
- ET.
